

Amendment to the Specification

Please replace the first paragraph at page 1, lines 2-4 of the specification with the following amended paragraph:

--This application claims the benefit of U.S. Provisional Application for Patent No. 60/165,018, filed November 12, 1999.--

Please replace the second paragraph at page 3 that starts on line 7 and ends on page 4, line 20 of the specification with the following amended paragraph:

--Retroviral protease inhibiting compounds are useful for inhibiting HIV proteases *in vitro* and *in vivo*, and are useful for inhibiting HIV (human immunodeficiency virus) infections and for treating AIDS (acquired immunodeficiency syndrome). HIV protease inhibiting compounds typically are characterized by having poor oral bioavailability. Examples of HIV protease inhibiting compounds include (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);(2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane (ABT-378); N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir); N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir); 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)-
 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4- t-butylamide;
 5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-
 amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-
 butylamide;
 [1S-[1R-(R-),2S*]-N¹ [3-[[[(1,1 -
 dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-
 hydroxy-1-(phenylmethyl)propyl]-2-[(2-
 quinolinylcarbonyl)amino]-butanediamide;
 VX-478; DMP-323; DMP-450; AG1343 (nelfinavir); BMS 186,318; SC-
 55389a; BILA 1096 BS; and U-140690, or combinations thereof. --

Please replace the second paragraph at page 11 that starts on line 9 under formula I and ends on page 12, line 2 of the specification with the following amended paragraph:

--A compound of formula I is an HIV protease inhibitor marketed by Abbott Laboratories under the tradename Norvir[®], with the common name ritonavir [(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane]. This and other compounds as well as methods for preparing the same are disclosed in U.S. Patent Nos. 5,648,497 and 5,541,206, the disclosures of which are herein incorporated by reference.--